Literature DB >> 283260

Breast gross cystic disease fluid analysis. I. Isolation and radioimmunoassay for a major component protein.

D E Haagensen, G Mazoujian, W G Dilley, C E Pedersen, S J Kister, S A Wells.   

Abstract

Human breast gross cystic disease (GCD) fluid was analyzed by sodium dodecyl sulfate-acrylamide gel electrophoresis, and four major proteins (GCDFP-70), GCDFP-44, GCDFP-24, and GCDFP-15) were identified. By fractionation techniques, these proteins were separated from one another. The GCDFP-70 was immunologically identical to human albumin and was present in GCD fluid at approximately a 100-fold lower concentration than in plasma. The GCDFP-44 was immunologically identical to human plasma Zn-alpha2-glycoprotein; however, it was present in GCD fluid at an approximately 50-fold higher concentration than in plasma. The GCDFP-24 was the major component protein of GCD fluid. It had progesterone binding activity, and immunologically it was identical to a component of human plasma; however, antisera that identified 30 separate components of plasma failed to identify the GCDFP-24 as one of these plasma proteins. The GCDFP-24 concentration in GCD fluid was approximately 100-fold higher than the plasma analog. The GCDFP-15 component was immunologically distinct from any plasma components, as judged by Ouchterlony analysis. It was, however, immunologically identical with a component of both human milk and saliva. As revealed by radioimmunoassay, plasma levels in normal subjects were 7-85 ng/ml. In patients with metastatic breast carcinoma, markedly plasma levels (150-30,000 ng/ml) of this protein were detected. Short-term tissue cultures of breast carcinoma explants released this protein into the culture medium.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 283260

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  31 in total

Review 1.  Biochemical study of cyst fluid in human breast cystic disease: a review.

Authors:  C L Enriori; J E Novelli; M del C Cremona; R J Hirsig; P J Enriori
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  Immunologic and steroid binding properties of the GCDFP-24 protein isolated from human breast gross cystic disease fluid.

Authors:  W G Dilley; D E Haagensen; C E Cox; S A Wells
Journal:  Breast Cancer Res Treat       Date:  1990-10       Impact factor: 4.872

3.  Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease.

Authors:  S H Dairkee; B M Ljung; H Smith; A Hackett
Journal:  Breast Cancer Res Treat       Date:  1987-10       Impact factor: 4.872

Review 4.  Epidemiology and endocrinology of benign breast disease.

Authors:  D Y Wang; I S Fentiman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

5.  Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features.

Authors:  G Mazoujian; G S Pinkus; S Davis; D E Haagensen
Journal:  Am J Pathol       Date:  1983-02       Impact factor: 4.307

6.  The ultrastructural localization of gross cystic disease fluid protein (GCDFP-15) in breast epithelium.

Authors:  G Mazoujian; M J Warhol; D E Haagensen
Journal:  Am J Pathol       Date:  1984-08       Impact factor: 4.307

7.  Estradiol stimulates synthesis of a major intracellular protein in a human breast cancer cell line (MCF-7).

Authors:  D P Edwards; D J Adams; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

8.  Hepatic clearance and metabolism in the rat of a human breast cancer associated glycoprotein (GCDFP-15).

Authors:  C A Toth; D E Haagensen; S Davis; N Zamcheck; P Thomas
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

9.  Antigens and antibodies cross-reactive to the murine mammary tumor virus in human breast cyst fluids.

Authors:  S S Witkin; N H Sarkar; D W Kinne; C N Breed; R A Good; N K Day
Journal:  J Clin Invest       Date:  1981-01       Impact factor: 14.808

10.  Fluoxymesterone stimulation of tumor marker secretion in patients with breast carcinoma.

Authors:  W G Dilley; D E Haagensen; G S Leight; S Ammirata; S R Davis; J S Silva; N Zamcheck; J J Lokich; S A Wells
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.